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The basic helix-loop-helix (bHLH) transcription factor family contains key regulators of cellular proliferation and differentiation as well as the
suspected oncoproteins Tal1 and Lyl1. Tal1 and Lyl1 are aberrantly over-expressed in leukemia as a result of chromosomal translocations, or other
genetic or epigenetic events. Protein-protein and protein-DNA interactions described so far are mediated by their highly homologous bHLH
domains, while little is known about the function of other protein domains. Hetero-dimers of Tal1 and Lyl1 with E2A or HEB, decrease the rate of
E2A or HEB homo-dimer formation and are poor activators of transcription. In vitro, these hetero-dimers also recognize different binding sites
from homo-dimer complexes, which may also lead to inappropriate activation or repression of promoters in vivo. Both mechanisms are thought to
contribute to the oncogenic potential of Tal1 and Lyl1. Despite their bHLH structural similarity, accumulating evidence suggests that Tal1 and
Lyl1 target different genes. This raises the possibility that domains flanking the bHLH region, which are distinct in the two proteins, may
participate in target recognition. Here we report that CREB1, a widely-expressed transcription factor and a suspected oncogene in acute
myelogenous leukemia (AML) was identified as a binding partner for Lyl1 but not for Tal1. The interaction between Lyl1 and CREB1 involves the
N terminal domain of Lyl1 and the Q2 and KID domains of CREB1. The histone acetyl-transferases p300 and CBP are recruited to these
complexes in the absence of CREB1 Ser 133 phosphorylation. In the Id1 promoter, Lyl1 complexes direct transcriptional activation. We also
found that in addition to Id1, over-expressed Lyl1 can activate other CREB1 target promoters such as Id3, cyclin D3, Brca1, Btg2 and Egr1.
Moreover, approximately 50% of all gene promoters identified by ChIP-chip experiments were jointly occupied by CREB1 and Lyl1, further
strengthening the association of Lyl1 with Cre binding sites. Given the newly recognized importance of CREB1 in AML, the ability of Lyl1 to
modulate promoter responses to CREB1 suggests that it plays a role in the malignant phenotype by occupying different promoters than Tal1.
© 2007 Elsevier B.V. All rights reserved.Keywords: Acute myelogenous leukemia; Gene expression; Helix-loop-helix transcription factor; Lyl1; Tal1; CREB11. Introduction
The family of helix-loop-helix (HLH) transcription factors
(TFs) contains key regulators of lymphocyte development and
maturation such as E2A (TCF3), Id1, andTal1/SCL /TCL5 [1–4].
Two other basicHLH (bHLH)TFs, Lyl1 and Tal2, are structurally
closely related to Tal1 but their functions are largely unknown.☆ This work was supported by grants from NCI Canada, US and Canadian
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doi:10.1016/j.bbamcr.2007.11.015Tal1 and Lyl1 were initially identified as over-expressed proteins
arising from chromosomal translocations in T-cell acute lympho-
blastic leukemia (T-ALL). This suggested their possible involve-
ment in the malignant phenotype [5–12]. Tal1 and Lyl1 are also
expressed at lower levels in normal tissues, such as CD34+ pro-
genitor cells, fetal liver and HUVEC cells, consistent with their
contribution to hematopoiesis. Lyl1 is highly expressed in
heart, lung, testis and placenta, where Tal1 expression is low or
absent. Tal1 is required for embryonic hematopoiesis as its
ablation leads to failure of yolk sac formation and early lethality
[13]. In addition, Tal1 is needed for the establishment of de-
finitive hematopoiesis, megakaryopoiesis and short-term repo-
pulating capacity of hematopoetic stem cells (HSC), but not for
HSC self-renewal. [13–16]. By contrast, Lyl1 knockout
Table 1
Primers used for PCR amplification
Procedure Primers
ChIP Id1F 5′-CCAGTTTGTCGTCTCCATGG-3′
Id1R 5′-CTCAGACCGTTAGACGCCAGG-3′
Id2F 5′-GCCCACACTAAGCCTGTCGT-3′
Id2R 5′-CAGTTCACTGCAACCCATCG-3′
Id3F 5′-AACCTCAGCTTCACCGCAAT-3′
Id3R 5′-CACAGCTCCTCCGAGGTCAT-3′
Id4F 5′-GCAGGAACTTCGCTCTCTCTTT-3′
Id4R 5′-ATGGGAAGGGCACTCCATT-3′
CycD3F 5′-TACATCGTGAGGCTTTCGAG-3′
CycD3R 5′-CTCTAGTCACCCAGGAAACAATTT-3′
Egr1F 5′-CTAGGGTGCAGGATGGAGGT-3′
Egr1R 5′-GCCTCTATTTGAAGGGTCTGG-3′
Brca1F5′-GCCGCAACTGGAAGAGTAGA-3′
Brca1R5′-ACAGAAAGAGCCAAGCGTCT-3′
Btg2F5′-CCTCCTTTCAGAGCTCTCAGTC-3′
Btg2R5′-CTCGCTGTCGTCAGTGCTA-3′
BambiF5′-GGGGCACCCAAAAGAAGC-3′
BambiR5′-CTGCGCGTCAGTGACCTTC-3′
mRNA Id1F 5′-TCAAGGAGCTGGTGGCCA-3′
Id1R 5′-GACGTGCTGGAGAATCTCCAC-3′
Id2F 5′-TGATCATCTTCCCAGGGTGT-3′
Id2R 5′-AGATTGGGCAATTCCTGGTG-3′
Id3F 5′-CTTCACCAAATCCCTTCCTG-3′
Id3R 5′-GCCTTGGCATAGTTTGGAGA-3′
Id4F 5′-GGATGAGGAAATGCTTGGAT-3′
Id4R 5′-TCTTTGGAGGAAGGAAAGCA-3′
Lyl-1 F5′-CCGAAGAAGGACCAGTGAAG-3′
Lyl-1 R5′-ATGACTGCTCTGCCATGTTG-3′
GAPDH F 5′-ATCATCAGCGCCTCCTG-3′
GAPDH R 5′-CTGCTTCACCACCTTGA-3′
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as severe deficits in competitive repopulation assays [17]. The
absolute requirement for Tal1 but not for Lyl1 in early hema-
topoiesis indicates that the two molecules have distinct, rather
than redundant cellular functions. This view is also supported
by enforced expression studies. Cord blood cells with enforced
Tal1 expression are induced to differentiate towards the ery-
throid lineage while neutrophil and B-cell differentiation are
blocked [18]. By contrast, enforced Lyl1 expression promotes
differentiation towards both pro-erythrocytic and pro-mega-
karyocytic paths suggesting effects on earlier progenitors [19].
Differences between Tal1 and Lyl1 phenotypes caused by
either over-expression or ablation of the genes cannot be read-
ily explained at the molecular level. The bHLH domains of
the two TFs are functionally interchangeable [20] while the
remaining, albeit distinct amino-acid sequences, have no as-
cribed functions. Nevertheless, Tal1 and Lyl1 have distinct in
vitro binding signatures [21]. By extension, this raises the pos-
sibility that different promoters are regulated in vivo. Micro-
array data in T-ALL showed that leukemias with high Tal1
expression have distinct gene expression patterns compared to
those with high Lyl1 expression [22].
The cyclic AMP receptor element binding protein 1(CREB1)
is a ubiquitously-expressed 43 kDa basic/leucine zipper TF
that is critical to a range of physiological processes such as me-
mory, factor-dependent cell survival, and glucose metabolism.
CREB1 binds to an eight base pair consensus sequence in the
promoters of target genes, by association with itself or with other
members of the CREB/ATF family[23–25]. Recruitment of the
transcriptional co-activators p300 and CBP to CREB1, requires
phoshorylation of CREB1 serine 133 [26]. Over-expression of
this phosphorylated CREB1 has been associated with increased
growth and survival of leukemic cells, myeloproliferative syn-
drome with splenomegaly in transgenic mice and increased risk
of post-chemotherapy relapse in AML patients [27,28]. Among
the identified CREB1 target genes are Id1 and Id3, inhibitors of
differentiation that can also promote cellular immortalization,
cyclin D3 and cyclin A1 implicated in cellular proliferation, and
the anti-apoptotic protein Bcl2, to name a few.
While investigating the factors involved in Id1 promoter
regulation in leukemic cells we observed the loss of Lyl1-
dependent transcriptional activation caused by mutation of a
critical Cre site. This suggested a possible interaction between
Lyl1 and CREB1. Since the bHLH motif of Lyl1 regulates
interactions with E12/E47 and we observed no direct interaction
between this domain and CREB1, we hypothesized that other
Lyl1 domains may interact with CREB1. Upon dissection of the
Lyl1 molecule we found that the N terminal 140 aa domain
participates in protein-protein interactions, in yeast two-hy-
brid assays (unpublished observations). These observations
prompted the present study in which we describe the molecular
mechanism of the interaction between Lyl1 and CREB1 and
further show that Lyl1 can up-regulate several previously
identified CREB1 targets. We find that through its N terminal
domain Lyl1 interacts with both Q2 and KID domains of CREB1.
The transcriptional co-activators p300 and CBP are recruited to
the complex and do not require CREB serine 133 phosphoryla-tion. Unexpectedly, ChIP- chip experiments using a CpG island
representation of the human genome revealed that co-regulation
by Lyl1 and CREB1may bewidespread, as∼50% of all genomic
targets identified were common between CREB1 and Lyl1 chips.
Since precise timing of CREB1 phosphorylation is essential for
the proper execution of cellular programs, part of the oncogenic
potential of Lyl1 may involve its ability to untimely recruit p300/
CBP co-activators to un-phosphorylated CREB1. Furthermore,
since Tal1 does not interact with CREB1, these observations
may explain some of the differences between Tal1-/- and Lyl1-/-
phenotypes.
2. Materials and methods
2.1. Cell culture and transient transfections
All cell lines were grown in RPMI 1640 media supplemented with 10% FCS
and antibiotics. For stable expression, pMIK-HA-Lyl1 or pMIK-HA empty
vector was electroporated into K562 cells and antibiotic resistant clones were
selected in 0.8 mg/mL G418. DMRIE-C or Lipofectamine and Optimem media
(Invitrogen) were used for transient transfection of 1.5 X 106 suspension cells or
0.5 X 106 adherent cells.
2.2. Plasmids
The pMIK-HA plasmid was supplied by O. Yoshie (Shionogi Institute for
Medical Science, Settsu-shi, Osaka 566-0022, Japan) and was previously des-
cribed [29]. To generate pMIK-HA-Lyl1, full-length human Lyl1 was amplified
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Lyl1-FL contained full-length Lyl1 cloned at 5′ Eco RI and 3′Hind III sites in the
pVP16 vector (MATCHMAKER Two-Hybrid Assay Kit from Clontech). Lyl1
deletion mutants were PCR amplified with Pfu (Stratagene) from the full-length
plasmid, with primers:
P1 (5-'CCGGAATTCATGACTGAGAAGGCAGAG-3′) and
P2 (5′-CCCAAGCTTCACGCGCCGGGCCACCTTCTG-3′) for the N-term-
inal 140 aa (Lyl1 NT); P3 (5′-CCGGAATTCCTGGACCTGGCTGAGGGGCAC-
3′) and
P4 (5′-CCCAAGCTTCCTGCGTCCGGATCCCCG-3′) for aa 125 to 267
(Lyl1 ΔN). Constructs were verified by sequencing and cloned EcoRI-BamH3
in the VP16 vector. Id1 promoter luciferase constructs were generously provided
by Robert Benezra (Memorial Sloan-Kettering, New York). Gal4-CREB, Gal4-
CREBS133A were obtained from William Roesler (University of Saskatchewan).
Gal4-p300 and Gal4-CBP were obtained from Neil Perkins (University of Dundee,
Scotland). The genomic E1A expression plasmid was a gift from E Zacksenhaus
(University of Toronto). The E47 expression plasmid pSV2B E2-5 was obtained
from J.C.Cross (University of Calgary). Truncated CREB constructs were generated
by PCR with Pfu (Stratagene) confirmed by sequencing and cloned 5′EcoRI and 3′
HindIII into the Gal4 vector. For full length CREB the primers were FL-sense(s): 5′-
CCGGAATTCGGATCCATGACCATGGAATCTGGA-3′and FL-antisense (as):
5′-CCCAAGCTTGCGGCCGCATCTGATTTGTGGGAGTA-3′; for Q1, KID,
and Q2 domains FL-s and Q2-as: 5′-CCCAAGCTTGCGGCCGCTGCTGCT-
TCTTCAGCAGG-3′; for Q1 and KID domains FL-s and Kid-as: 5′-CCCAA-
GCTTGCGGCCGCAGTCTCCTCTTCAGACTT-3′; for Q1 domain FL-s and
Q1-as: 5′-CCCAAGCTTGCGGCCGCAGACTGAACTGTTTGGAC-3′; for Q2
domain Q2-s: 5′-CCGGAATTCGGATCCTCAGCACCTGCCATCACC-3′ and
Q2-as; for KID domain Kid-s: 5′-CCGGAATTCGGATTTTAGATTTCAACTA-
TTGCA-3′ and Kid-as; and for bZIP domain bZip-s: 5′-CCGGAATTCGGA-
TCCAAGAGAGAGGTCCGTCTA-3′ and FL-as.
2.3. Antibodies
Rabbit polyclonal anti-CREB (cat#06-863), anti-CREB phosphoserine 133
(cat#06-519), and mouse monoclonal mixed anti p300/CBP (cat#05-267)
were from Upstate, NY. Biotechnology (Lake Placid,NY). During the course of
this work a commercial Lyl1 antibody preparation (sc-46158) was made avail-
able from Santa Cruz Biotechnology (Santa Cruz, California). A dilution of
1:200 of this antibody was used for ChIP experiments. Rabbit Gal4 DBD
antibody (sc-577), Id1 antibody (sc-488), normal mouse serum (sc-2025) and
normal rabbit serum (sc-2027), goat anti-rabbit HRP (sc-2004) and goat anti-
mouse HRP (sc-2005) were also from Santa Cruz Biotech. Antibody to actin
was from Sigma (A-2066). Anti hemagglutinin antibody (αHA, clone 12CA5)
was obtained from Roche.
2.4. Electrophoretic mobility shift (EMSA)
Nuclear extracts were prepared as previously described [30]. Briefly, the cells
were washed twice with ice-cold PBS, re-suspended in hypotonic lysis buffer
[12.0 mM Hepes (pH 7.9), 4.0 mM Tris (pH 7.9), 0.6 mM EDTA, 10 mM KCl,
5.0 mM MgCl2, 1 mM Na3VO4, 1.0 mM Na4P2O7, 1.0 mM NaF, 0.6 mM di-
thiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin, 2 mg/
ml leupeptin, and 2 mg/ml pepstatin A] and lysed on ice by repeated passage
through a 25G 11/2′' needle. The nuclear fraction obtained by centrifugation at
12,000 g for 20 s was layered on top of a 30% sucrose solution of the above buffer
and sedimented by centrifugation at 15,000 rpm for 30 min at 4 °C. Nuclei were
lysed on ice in the above buffer supplemented with 300 mM KCl and 20%
glycerol with occasional vortexing for 30 min. Lysates were stored at –70 °C.
Complementary double stranded oligonucleotides were annealed and labeled
with [32P] γATP in the following reaction: 50 ng DNA, 5 μL polynucleotide
kinase buffer, 150 μCi [32P] γATP, 1.5 μLT4 PNK (New England), and H2O to
50 μL. Labeled probes were purified on G25 nick columns (Pharmacia).
Typically, probes with specific activities between 5-10 X 104 cpm per 0.25 ng of
DNAwere used. For the binding reaction, nuclear lysates (15-30 μg of protein)
were pre-incubated on ice for 30 min with 3 μg of poly (dI-dC)-poly (dI-dC),
competing oligonucleotide probes, normal serum or antibody, in 20 mMHEPES
(pH 7.9), 50 mM KCl, 1.0 mM EDTA, 5% glycerol and a reaction volume of
30 μL. This was followed by 20min incubation at room temperature with 0.25 ngof 32P-labelled oligonucleotide probe. Nondenaturing 5% gels were run in 0.5 X
TBE at 10 V/cm for 4.0 hrs. Gels were dried without fixing and processed for
autoradiography.
The double-stranded oligonucleotide probes used were:
wt CRE: 5′-GAATGGGTGACGTCACGGGCC-3′
mCRE: 5′-GAATGGGTGGTAGTACGGGCC-3′
(mutated sequences underlined) annealed to their complementary counterparts.
2.5. RT-PCR analysis
For real-time reverse-transcriptase PCR (qRT-PCR), RNA was prepared
from cell lines and patient samples with an RNeasy kit (Qiagen) and converted
to cDNA using TaqMan RT reagents (Applied Biosystems). qRT-PCR was
performed with a PE Prism 7700 light thermocycler on 20-40 ng using SYBR
Green PCR Master Mix (Applied Biosystems). Id1 mRNA copy number was
calculated using the ΔΔCt method (ABI Prism 7700 User Bulletin #2).
Amplification of endogenous promoters immunoprecipitated by ChIP was
performed using PlatinumTaq and 4.0 μl of immunoprecipitated template (1:10
of total yield), as follows: 4 min at 94 °C (denaturation), 30 cycles at 94 °C for
30 s, 59 °C for 45 s and 72 °C for 45 s (amplification), and a final extension at
72 °C for 10 min. Primers used for qRT-PCR and PCR amplification of ChIP
promoter DNA are shown in Table 1.
2.6. Chromatin immunoprecipitation (ChIP)
Immunoprecipitation of chromatin crosslinked to the endogenous promoters
was performed as previously described [31]. The complete protocol followed is
available at http://genomecenter.ucdavis.edu/farnham/farnham/.
2.7. Microarray hybridization and analysis
The complete protocol followed is available at www.microarrays.org. Briefly,
immunoprecipitated and genomic DNA was dried and prepared for PCR ampli-
fication by annealing to degenerate primers with a constant 5′ sequence, followed
by two cycles of primer extension with Sequenase (Perkin Elmer) (round A).
Amplification of thisDNAwasperformedwith primers complementary to the fixed
sequence in two rounds of PCR (B1 and B2) with 25 cycles per round. Amino-allyl
dUTP was incorporated into templates in round B2. Templates were labeled with
Alexa dyes A555 (genomic DNA) and A647 (ChIP DNA) according to the manu-
facturer's protocol (Molecular Probes). After washing to remove un-incorporated
dyes, 3 μg of total genomic and ChIP DNA were hybridizedfor 16 hr to CGI
microarrays. Intra- and inter-array normalization was performed with TIGR
software (The Institute for Genomic Research) Bad spots and spots with intensities
less than 1500 in either channel (b15 times background intensity) were excluded
from further analysis. Only spots present in at least 3 of 4 slides and with intensity
greater than 2 fold for DNA from ChIPs with αHA or αCREB, relative to total
genomic DNA, were further considered.
2.8. Immobilized template assay
Pull-down assays with biotinylated DNA were performed as described
previously [32] Single-stranded oligonucleotides corresponding to the reverse
strand of a 3XGal4 promoter were synthesized and biotinylated according to the
protocol supplied by the manufacturer (Pierce, cat #89818). Following an-
nealing with the complimentary strand, 200 ng of this template was bound to
streptavidin beads, washed twice with binding buffer (20 mM HEPES, pH 7.9,
100 mM NaCl, 5.0 mM MgCl2, 0.5 mM EDTA, 0.01% NP40, 10% glycerol)
and blocked for 15 min at room temperature in 50 μL binding buffer containing
0.1 mg/mL BSA. The reaction was supplemented with 4.5 μg of poly (dI: dC),
4.5 μg sheared salmon sperm DNA, protease inhibitors (Roche) and incubated
on ice for another 15 min. Nuclear extract protein (250 μg) was finally added
and the incubation was continued at 4 °C for 4.0 hrs with mixing. The beads
were washed three times with binding buffer supplemented with 1 mM DTT,
1 mg/mL BSA and protease inhibitors. Proteins were eluted from the beads in
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Fig. 1. Lyl1 and Id gene expression. (A) Real time PCR analysis of Lyl1 and Id genes expression in 19 AML patients after normalization to internal GAPDH levels.
Empty bars show Lyl1 expression. Three replicate experiments were performed for each clinical sample. Results are shown as means and standard errors. (B) Diagram
of Id promoters showing the location of fragments amplified by conventional ChIP experiments (“Amplified Fragment”) relative to the location of the proximal
promoters for each gene. For Id1, Id3 and Id4 CREB1 clusters were found located in regions with high conservation in mammals. Illustrations were produced using the
Genome Browser at UCSC (www.genome.ucsc.edu). (C) Validation of Id targets. Conventional ChIPs with pre-immune (PI) serum or HA antibody (αHA) were
performed using cells expressing HA-Lyl1. For comparison, the PCR amplification obtained in the absence of template (NTC) or with 10% of the total chromatin input
(input) is shown. Cre sites are indicated by filled ovals. For Id1 the Cre site at position -927 is depicted by a larger symbol; this site together with flanking sequences
(depicted in Fig. 2A) constituted the double-stranded (ds) oligonucleotide sequence used in the EMSA experiments. Arrows indicate the position of PCR primers
relative to transcription start sites. Graphs show expression levels by real time PCR for each Id gene in HA and HA-Lyl1 expressing cells after normalization to internal
GAPDH levels. Results of triplicate experiments are shown.
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αGal4 antibody.Table 2
Co-regulated genes in AML
CREB1 Lyl1 Tal1 E47 CREB1&Lyl1 CREB1&Tal1 E47&Lyl1
ALL 827 515 400 391 48 (7.1%) 8 (1.3%) 17 (3.7%)
AML 390 283 375 437 68 (21.7%) 4 (0.5%) 4 (0.6%)
A published gene profile Affymetrix data set for ALL and AML patients [35]
was analyzed for genes whose expression correlate (rN0.67) with those of
CREB1, Lyl1, Tal1, or E47 (TCF3). Total numbers (and %) of genes in common
for the indicated combination of TFs is shown.3. Results
3.1. Lyl1 up-regulates endogenous Id1 and Id3 expression
The bHLH domains of Lyl1 and Tal1 were found to be inter-
changeable in domain-swapping experiments [20]. This contrasts
with the observations that their knock-out phenotypes are distinct
[17]. Thus, we were motivated to investigate if other Lyl1 do-
mains are involved in protein-protein interactions that confer
transcription specificity. We used the longer, 140 aa N-terminal
domain of Lyl1 as bait in a yeast two-hybrid screen of a K562
mRNA expression library and identified several interacting
proteins (not shown). In this initial screen CREB1 was not
identified as a binding partner. However, in leukemic cell lines we
observed abrogation of Lyl1-dependent transcriptional activation
caused bymutation of a critical CREB1 binding site in the murine
Id1 promoter. Mutation of the nearby E2A binding site, where
Lyl1-E12/E47 complexes would be expected to form, did not
significantly alter the rate of transcription (see Supplementary
Information). This suggested that Lyl1-dependent transcriptional
activation was driven from the Cre and not the Ephrussi box (E
box) site. Binding of Lyl1 to the Cre but not the E box site was
verified by EMSA experiments (see Supplementary Information).From the outset we narrowed down the investigation to
previously-identified CREB1 gene targets and focused on the Id
family of proteins because of their well-documented roles in
hematopoiesis and because of the presence of conserved regu-
latory Cre sequences in their promoters. Ids inhibit cellular dif-
ferentiation by preventing bHLH complexes from binding to
promoter DNA. We measured the expression of Lyl1, Id1, Id2,
Id3, and Id4 mRNA 19 AML samples using real-time PCR with
correction for GAPDH expression. Significant correlations were
found between the expression of Lyl1 and those of Id1 or Id3
(Fig. 1A ). Id1 and Id3 (as well as Id2 whose expression in these
patient samples did not correlate to that of Lyl1), were previously
recognized as CREB1 targets. To further investigate a functional
link between Lyl1 and Id's, we enforced expression of HA-tagged
Lyl1 or empty HA vector in K562 cells and determined the
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Fig. 3. Formation of a three-way complex containing Lyl1, CREB1, and p300. (A) Left: Lyl1 interacts with CBP and E1A. K562 cells co-transduced with 0.5 μg of the
indicated plasmids, a luciferase reporter and a β-gal expression plasmid for data normalization. Empty pcDNA3 vector was added to maintain a constant amount of
DNA in the transfection reaction. Right: protein expression of the various constructs compared to empty vector in crude lysates. (B) Lyl1 but not Tal1 forms tri-partite
complexes with CREB1 and p300. Left panel. Pull-down assays from COS7 cells co-transduced with tagged Lyl1, CREB1 and p300 were performed with a
biotinylated oligonucleotide, as described above. Right panel. A similar experiment in which Flag-Tal1 was expressed and its association with CREB1 was monitored.
Representative western blots showing protein expression in 50 μg of crude lysates is shown for each experiment.
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Id1 through Id4. Evolutionarily conserved clusters of CREB1
binding sites were identified and primers were designed to am-
plify DNA templates obtained by chromatin immuno-precipita-
tion (ChIP) (Fig. 1B). Following pull-downs with HA antibody
or pre-immune serum we observed the association of HA-Lyl1Fig. 2. Lyl1-CREB1 interactions involve a conserved Cre site of the Id1 promoter. (A
cells, expressing transfected HA-Lyl1 and CREB1, are incubated with a 32P-labelled o
Complexes are competed by excess cold wild type Cre but not by excess mutant Cre
italics. Expression of HA-Lyl1 in K562 cells transduced with this construct or with
complexes with endogenous and exogenous CREB1. Nuclear extracts from COS7
incubated with pre-immune serum (PI) or HA antibody (αHA) and then incubated w
arrowhead shows a slower-migrating complex that was observed with nuclear extract
domains that were fused to Gal4DBD. Bottom left: results of pull-down experiments
constructs were incubated with a biotinylated ds oligonucleotide encoding three ta
agarose, resolved by SDS-PAGE, blotted with αHA. The same blot was stripped and r
to empty vector (50 μg total protein/lane). (C) Identification of the Lyl1 domain that in
VP16 transcriptional activator and the construct's ability to interact with Gal4DBD-CR
protein expression in crude lysates.with Id1, Id3, and Id4 promoters. Furthermore, we noted the up-
regulation of Id1, Id3 and Id4 mRNA expression in these same
cells (Fig. 1C). Interestingly, we did not observe a correlation in
clinical samples between the expression of Lyl1 and that of Id4.
Id4 expression was shown to vary greatly according to the
methylation status of its promoter in different cell lines [33]. Thus,) Left panel. Specific complexes (arrows) form when nuclear lysates from COS7
ligonucleotide probe, encoding the Cre site at position -927 in the Id1 promoter.
(mCre) oligonucleotides. The 6 bp Cre site is boxed and mutations are shown in
empty vector in shown in the left panel. Right panel. Lyl1 forms CRE-bound
cells were harvested 48 h after transfection with the indicated plasmids, pre-
ith the probe. The arrow identifies the position of a supershifted complex. The
s from cells co-expressing HA-Lyl1 and CREB1. (B) Top: a diagram of CREB1
. COS7 nuclear extracts expressing transfected HA-Lyl1 and Gal4DBD-CREB1
ndem Gal4 binding sites. Bound proteins were pulled-down with streptavidin-
e-probed with αGal4. Bottom right: protein expression in crude lysates compared
teracts with CREB1. Full-length or truncated Lyl1 was fused downstream of the
EB1 was determined by means of two-hybrid assays in COS7 cells. Right panel:
510 S. San-Marina et al. / Biochimica et Biophysica Acta 1783 (2008) 503–517epigenetic regulation of Id4 expression may be different in cli-
nical samples and in the K562 erythroleukemia cell line and these
differences may account for the observed results. Due to the
predicted presence of nearby E2A binding sites (see Fig. 4A) the
observed effects cannot be solely attributed to Lyl1-CREB1
interactions but taken together, the data are suggestive of a link
between the expression of Lyl1 and those of Id1 and Id3, two
previously identified CREB1 targets.
3.2. A three-way complex containing Lyl1, CREB1 and p300
binds DNA
To investigate the possibility that CREB1 and Lyl1 co-regulate
gene expression, we performed template matching analysis [34]
using ALL and AML gene expression data from a published
report [35]. First, we identified genes whose expression patterns
matched the expression of CREB1, Lyl1, Tal1, and E2A, ninety-
nine times out of a hundred (pb0.01). Then, common genes were
identified in CREB1 and Lyl1, CREB1 and Tal1, and E2A and
Lyl1 groups, for both ALL and AML. For the AML data, 1 in 5
genes were common between CREB1 and Lyl1. By comparison,
approximately 1 in 100 genes were common betweenCREB1 and
Tal1 or between Lyl1 and E2A (Table 2).Fig. 4. Lyl1 binds, acetylates Id1 promoter in vivo. (A) Diagram of an upstream fragm
(thick line between amplifying primers). Boxes and ovals represent E box and Cre bin
is enlarged for orientation. Thin lines represent the average length of sonicated chroma
107 K562 cell nuclei expressing empty vector (CT) or enforced HA-Lyl1 (Lyl1) wer
enrichment of the promoter due to Lyl1 expression. QPCR results were corrected for p
by interpolation to standard curves determined for each primer set. HCL normaliz
complexes along the Id1 promoter in two cell lines. Top: the results depicted in (B) fo
groups for each set of ChIP-qPCR data. Bottom: similar experiments with the TG 1A
commercial antibody to Lyl1 (see Methods). Mock assays, i.e. no chromatin input wThe above results suggest that Lyl1 and CREB1 may co-
regulate a number of genes in leukemia. Since ChIP cannot
specify where a protein binds in a sequence of immunopreci-
pitated DNA, we used EMSA to determine if the two TFs in-
teract at the molecular level. Fig. 2A (left panel) shows the
results of experiments in which COS7 nuclear extracts ex-
pressing exogenous CREB1 and HA-Lyl1 retard migration of a
32P-labelled oligonucleotide probe containing a Cre site con-
served in the human and murine Id1 promoters. The probe
sequence corresponds to nucleotides -926 to -913 in the human
Id1 promoter. In the absence of cold competitor, two prominent
complexes (arrows) were identified following a relatively brief
period of exposure to autoradiography (∼4 hours). These com-
plexes became fainter when lysates were pre-incubated with
increasing amounts of cold competitor and eventually disap-
peared at 100 fold molar excess of the cold competitor. A cold
competitor containing a mutation in the Cre site but retaining the
wild type flanking sequences had no effect, thereby showing that
protein complexes bound to the Cre site (Fig. 2A, 100XmCRE).
To verify that the observed complexes contained CREB1 and
Lyl1 we performed antibody supershifting experiments (Fig. 2A
right panel). Nuclear extracts from COS7 cells transduced with
empty pcDNA3 vector were pre-incubated with pre-immuneent of the human Id1 promoter centered on a 189 bp region of conserved DNA
ding sites, respectively. The Cre sequence at -927 was used in EMSA and the site
tin (∼300 bp). (B) ChIP-qPCR analysis of the Id1 promoter depicted in A. 1.5 X
e used for ChIP with the indicated antibodies in order to determine the relative
rimer amplification efficiency and results were expressed as ng of starting DNA
ation and clustering was done using TIGR software. (C) Binding of HA-Lyl1
r K562 cells expressing HA-Lyl1 are shown as a ratio between HA-Lyl1 and CT
cell line that expresses high endogenous Lyl1 levels; ChIP was performed using a
ere negative (not shown).
Fig. 5. Effect of Lyl1 on CREB1-driven promoters. (A) Transcriptional activation
of CREB1-driven promoters. Promoter-luciferase constructs were co-transfected
with empty vector or HA-Lyl1 (0.5, 1.0, or 2.0 μg of plasmid) in K562 cells.
Transfection efficiencies were similar between experiments, as determined by the
amount of co-transfectedβ-gal. Id1 promoter constructs contained 1.5 kb or 210 bp
of Id1 upstream sequence (see Supplementary Information S1) fused to a luciferase
reporter. (B) Association of Lyl1 with known CREB1 targets. DNA from ChIPs
performedwith the indicated antibodies was amplified with PCR primers designed
to span proximal CREB1 binding sites (MATCH similarity score relative to
CREB1 matrix N0.85). The ordinate represents the amount of ChIP template (ng)
that was calculated by interpolating the experimentally-determined Cts with cali-
bration curves obtained from serial dilution experiments with total genomic DNA.
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shifted complex containing endogenous CREB1 is clearly vi-
sible (compare lanes 1 and 2). This super-shifted complex is also
visible with αHA in cells that were transduced with HA-Lyl1
(lane 5), an indication that transfected Lyl1 binds to the pre-
existing CREB1 complex. In cells co-transduced with HA-Lyl1
and CREB1 two additional, probably non-specific complexes
appear (arrowheads).
To identify the interacting CREB1 domains we co-expressed
Gal4-fused CREB1 constructs together with HA-Lyl1 in COS7
cells and performed pull-down assays with a 3′ biotinylated
oligonucleotide containing three tandem Gal4 binding sites.
CREB1 constructs included a full-length wild type plasmid, a
S133A mutant construct that is unable to recruit p300/CBP
[36,37] and domain deletion mutants. Precipitated proteins were
separated on western blots and probed with αHA or αGal4. The
results are shown in Fig. 2B. Importantly, Lyl1 interacted with
the CREB1 S133A mutant that is unable to recruit p300/CBP,
thereby showing that CREB1-Lyl1 interactions do not require
Ser133 phosphorylation. Furthermore, experiments with dele-
tion mutants show that Lyl1 interacts separately with Q2 and
with KID domains of CREB1.
To identify Lyl1 domains that interact with CREB1, we used a
two-hybrid system strategy. Lyl1 domains cloned downstream of
the yeast VP16 transactivator were co-transfected in COS7 cells
together with Gal4-CREB1 and a reporter vector expressing lu-
ciferase driven from tandem Gal4 binding sites (Fig. 2C). An
interaction recognized by a 2.5 fold increased in luciferase acti-
vity, was observed betweenCREB1 and theN-terminal domain of
Lyl1 (Lyl1N). The interaction was abrogated upon deletion of this
domain in the Lyl1ΔN construct, which demonstrated that the rest
of the Lyl1 molecule was not necessary.
The bHLH domains of Tal1, E47, and Lyl1 are structurally
similar. In Tal1 and E47, they mediate interactions with p300
and the CREB-binding protein (CBP), two homologous tran-
scriptional co-activators. Interaction between Lyl1 and these
proteins was not previously shown but was expected to occur,
and is shown in Fig. 3A. Enforcing the expression of E1A
abolishes all interactions with CBP, including that of Lyl1, in
agreement with previous results.
Having observed separate interactions between Lyl1 and
CREB1 and Lyl1 and CBP, we next investigated the formation
of a tripartite Lyl1, CREB1 and p300 complex with DNA, by
co-transfecting expression plasmids into COS7 cells. Protein
complexes assembled on a biotinylated oligonucleotide con-
taining 4 tandem GAL4 binding sites were pulled down with
streptavidin-agarose and identified by Western blot analysis
(Fig. 3B left panel). Flag-p300 was pulled down with Gal4-
CREB1 but not with Gal4-CREB1 S133A (compare lanes 1
and 4), in keeping with previous observations that p300 and
CBP do not interact with this CREB1 phosphorylation mutant.
Co-expression of HA-Lyl1 with p300 and CREB1 resulted in a
complex of all three proteins that was pulled down (lane 2) but
in the absence of CREB1, Lyl1 and p300 did not bind to the
Gal4 promoter (compare lanes 2 and 3). Previously we showed
that Lyl1 establishes independent interactions with the Q2 and
KID domains of CREB (see Fig. 2B) and that it interacts withCREB S133A. P300 is recruited to the complex, presumably by
Lyl1 (compare lanes 4 and 5). In similar pull down experiments
performed with Tal1 we did not observe a Tal1-CREB1 inter-
action (Fig. 3B, right panel).
To summarize, using EMSA, promoter pull downs and two-
hybrid assayswe observed that Lyl1 interactswithCREB1 and that
a three-way complex of these proteins with p300 can assemble.
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Recruitment of the transcriptional apparatus to promoter
DNA is hindered by close interactions between positively
charged histones and the negatively charged DNA backbone.
Histone acetylation relieves the spatial constraints and facil-
itates the positioning of the transcriptional machinery at the
start site. The histone acetyltransferase (HAT) activity of p300/
CBP is known to be involved in many instances of gene up-
regulation. Since we previously observed the formation of
Lyl1-CREB1-p300 complexes in COS7 cells, we used ChIP to
investigate if these complexes form in vivo and alter the ac-
etylation status of core histones within the Id1 promoter. This
could explain the up-regulation of Id1 noted in HA-Lyl1 tran-
sfected cells. Fig. 4A shows a diagram of the Id1 promoter with
the distribution of predicted Cre and E box sites relative to
the average fragment length of the sonicated chromatin input
for ChIP (∼300 bp). The region represented is centered on a
189 bp sequence that corresponds to the minimal Id1 promoter
in mouse fibroblasts and is conserved in the human promoter. In
transfection assays the 189 bp promoter is activated by Lyl1
(see further). Conventional PCR of ChIP DNA using primers to
amplify Cre -927 showed that HA-Lyl1 cells contained higher
levels of p300/CBP and acetylated histone H4 bound to the
promoter (not shown). In order to determine if this effect is due
to the presence of this conserved Cre site or, alternatively, whether
it extends to up-streamor down-stream regions in associationwith
other predicted Cre and E box sites, immunoprecipitaed chro-
matin was analyzed by quantitative RT-PCR with primers span-
ning the entire region shown in Fig. 4A. Results were corrected
for primer efficiency and expressed as nanograms of DNA by
reference to standard curves obtained for each primer set. WhenFig. 6. Overlap between Lyl1 and CREB1 genomic targets in ChIP-chip experimen
CREB1 pull-downs. DNAwas hybridized to 12 K CGI arrays. (B) Gene Ontology f
both Lyl1 and CREB1. (C) Common CREB1 and Lyl1 targets are enriched in geneanalyzed with TIGR software, we observed that empty vector and
HA-Lyl1 expressing cells cluster separately. The ratio between the
expression of HA-Lyl1, p300, acetylated H3 and acetylated H4 in
the two cell populations is shown in Fig. 4B. HA-Lyl1 bound to
multiple sites on the promoter, in keeping with the abundance of
predicted Cre and E box sites. However, the distribution of p300,
acetylatedH3 and acetylatedH4was uneven and peaked in region
5 which contains Cre -927 (Fig. 4C, top panel). Similar results
were obtained by a ChIP experiment that targeted endogenous
Lyl1 expression in the leukemia cell line KG 1A using a newly
commercialized human Lyl1 antibody preparation (see Methods)
(Fig. 4C, bottom panel).
In summary, enforced HA-Lyl1 expression in K562 cells
increased Id1 promoter acetylation, consistent with increased
recruitment of p300/CBP acetyltransferases to Lyl1 complexes
with CREB1. Lyl1-E2A complexes are predicted to form and
may also contribute to this effect.
3.4. Lyl1 transactivates CREB1 promoters
Next, we examined the effect of Lyl1 on transcriptional
activation of several previously-described CREB1-driven hu-
man promoters [25]. Lyl1 increased cyclin D3, Egr1, and Id1
transcriptional activation (Fig. 5A ) but had no effect on Bcl2 and
Bcl-xL promoters (not shown). ChIPs followed by qRT-PCR
amplification showed that both CREB1 and HA-Lyl1 bind to
endogenous cyclin D3 and Egr1 promoters (Fig. 5B). We also
tested the association of Lyl1 with three CREB1 promoter targets,
identified previously in PC12 cells: Btg2, Brca1, and Bambi. We
were unable to confirm association of CREB1 with any of these
targets in K562 cells, however, Lyl1 did associate with Brca1 and
Btg2. Neither TF associated with Bambi.ts. (A) Venn diagram depicting common clones identified in the HA-Lyl1 and
eatures associated with unique Lyl1 loci compared to genomic loci occupied by
s previously identified as CREB1 targets [39].
Table 3
Lyl1 and CREB1 genomic targets identified by ChIP-chip using CGImicroarrays
Common for
CREB1 & Lyl1
Distance from
known gene (bp)
Gene Name Description
0 AK125187 Hypothetical protein FLJ43197.
0 APP amyloid beta A4 protein precursor,
isoform a
0 ASCC3 activating signal cointegrator 1
complex subunit
0 BC006438 Hypothetical protein.
0 CACNA2D3 calcium channel, voltage-dependent,
alpha
0 COX7A2 cytochrome c oxidase subunit
VIIa polypeptide 2
0 DBR1 debranching enzyme homolog 1
0 DCC deleted in colorectal carcinoma
0 FAM19A5 family with sequence similarity
19 (chemokine (C-C motif)-like),
member A5
0 FLJ10726 FLJ10726 protein.
0 GMFB glia maturation factor, beta
0 LIAS lipoic acid synthetase isoform 1 precursor
0 M6PRBP1 mannose-6-phosphate receptor binding
protein 1
0 MKL1 megakaryoblastic leukemia 1 protein
0 MRPL27 mitochondrial ribosomal protein L27
isoform a
0 PCSK1N proprotein convertase subtilisin/kexin
type 1
0 PLCB1 phosphoinositide-specific phospholipase
C beta 1
0 PRDM8 PR domain containing 8
0 PTTG1 pituitary tumor-transforming protein 1
0 RFX2 regulatory factor X2 isoform a
0 SNAP91 synaptosomal-associated protein,
91 kDa homolog
0 ZNF665 zinc finger protein 665
27 HIST1H4H H4 histone family, member H
79 AK126015 Hypothetical protein FLJ44027.
262 MYST1 MYST histone acetyltransferase 1
308 TRH thyrotropin-releasing hormone
474 ME3 Hypothetical protein FLJ34862.
686 LOC120379 hypothetical protein LOC120379
1211 RPL9 ribosomal protein L9
1612 EME1 essential meiotic endonuclease 1
homolog 1 (S. pombe)
2794 SLU7 step II splicing factor SLU7
2858 AK127974 Hypothetical protein FLJ46089.
3102 WDR5 WD repeat domain 5
4277 HOXD4 homeobox D4
4476 BCKDK branched chain ketoacid dehydrogenase
kinase
4671 ERAS small GTPase protein E-Ras
6149 HOXD3 homeobox D3
7790 HOXD13 homeobox D13
9093 TMEM30A transmembrane protein 30A
9921 DBR1 Hypothetical protein FLJ20109.
Specific for CREB1 Only
0 ALS2CR11 amyotrophic lateral sclerosis 2
(juvenile)
0 EMX2 empty spiracles homolog 2
0 IL1RAPL1 interleukin 1 receptor accessory protein-
like 1
(continued on next page)
Table 3 (continued )
Common for
CREB1 & Lyl1
Distance from
known gene (bp)
Gene Name Description
Specific for CREB1 Only
0 BMS1L BMS1-like, ribosome assembly protein
0 MSL3L1 male-specific lethal 3-like 1 isoform a
0 ZNF677 zinc finger protein 677
0 CSMD3 CUB and Sushi multiple domains 3
0 LRPAP1 low density lipoprotein receptor-related
protein
0 COL14A1 COL14A1 protein.
0 TPR translocated promoter region (to
activated MET)
0 BRIP1 BRCA1 interacting protein C-terminal
helicase 1
0 MGC33648 hypothetical protein LOC133383
0 PCAF p300/CBP-associated factor
0 CRTC3 CREB1 regulated transcription
coactivator 3
0 FAM19A5 family with sequence similarity 19
(chemokine (C-C motif)-like),
member A5
0 DLX6 distal-less homeobox 6
0 ETS1 ETS1 protein.
0 HD huntingtin
0 C15orf33 hypothetical protein LOC196951
0 FANCD2 Fanconi anemia complementation
group D2 isoform
0 PLA2G4B phospholipase A2, group IVB
0 DLD dihydrolipoamide dehydrogenase
precursor
0 DHTKD1 dehydrogenase E1 and transketolase
domain
0 RAE1 Hypothetical protein FLJ44036.
0 IGSF4B immunoglobulin superfamily,
member 4B
0 HIST1H2BC Hypothetical protein.
0 MYRIP myosin VIIA and Rab interacting protein
0 ADAMTS10 ADAM metallopeptidase with
thrombospondin type 1
0 RNASET2 ribonuclease T2
0 WTAP Wilms' tumour 1-associating protein
isoform 1
0 KIAA1772 hypothetical protein LOC80000
0 ZRANB3 zinc finger, RAN-binding domain
containing 3
1 MAPKBP1 mitogen-activated protein kinase
binding protein
18 WTAP PNAS-132.
39 ZRANB3 Hypothetical protein FLJ38043.
109 DTWD1 DTWD1 protein.
158 LGI2 leucine-rich repeat LGI family,
member 2
186 HIST1H2BC H2B histone family, member L
341 EPHA10 EPH receptor A10 isoform 2
453 R3HDM1 R3HDM1 protein.
746 MMP25 matrix metalloproteinase 25 preproprotein
1123 ZNF425 zinc finger protein 425
1470 ZNF524 zinc finger protein 524
1635 KIAA1287 integrator complex subunit 2
2687 MEIS1 Meis1 homolog
4007 AKAP2 A kinase (PRKA) anchor protein 2
4836 CIDEC CIDEC protein.
5179 CDKN1B cyclin-dependent kinase inhibitor 1B
(continued on next page)
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Table 3 (continued )
Common for
CREB1 & Lyl1
Distance from
known gene (bp)
Gene Name Description
Specific for CREB1 Only
5484 IRX1 iroquois homeobox protein 1
6581 AK128093 Hypothetical protein FLJ46214.
7568 SEC61A2 SEC61A2 protein.
7889 BC047593 LOC440508 protein.
7911 AK096426 Hypothetical protein FLJ39107.
8050 ZIC5 zinc finger protein of the cerebellum 5
8186 AF271776 ATP synthase a chain (EC 3.6.3.14)
(ATPase protein 6).
8864 DKFZP781I1119 Hypothetical protein DKFZp686J16125.
9890 DLX5 distal-less homeobox 5
Specific for Lyl1 only
0 ADRB3 adrenergic, beta-3-, receptor
0 AKT1S1 AKT1S1 protein.
0 ASAH3L ASAH3L protein.
0 ATOH8 atonal homolog 8
0 C13orf24 C13orf24 protein.
0 C18orf54 hypothetical protein LOC162681
0 C3orf26 hypothetical protein LOC84319
0 C6orf173 hypothetical protein LOC387103
0 CRELD2 hypothetical protein LOC79174
0 DCDC2 doublecortin domain containing 2
0 DKFZp761B107 hypothetical protein LOC91050
0 DLG2 discs, large homolog 2, chapsyn-110
(Drosophila)
0 ELOVL5 homolog of yeast long chain
polyunsaturated
0 FBXO4 F-box only protein 4 isoform 1
0 LOC390927 hypothetical protein LOC390927
0 LOC442578 Hypothetical protein LOC442578.
0 MEIS1 Meis1 homolog
0 NTRK3 neurotrophic tyrosine kinase, receptor,
type 3
0 PDCD6IP programmed cell death 6 interacting
protein
0 PIAS1 protein inhibitor of activated STAT, 1
0 RPS25 ribosomal protein S25
0 SERPINB6 MSTP057.
49 PDCD6IP programmed cell death 6 interacting
protein
114 AJ968414 Cysteine-rich with EGF-like Domains 2
(CRELD2) beta isoform.
241 PHACTR3 OTTHUMP00000031426.
286 ASAH3L N-acylsphingosine amidohydrolase
3-like
613 TBC1D17 TBC1 domain family, member 17
742 EFNA5 ephrin-A5
1378 ARL1 ADP-ribosylation factor-like 1
1403 MXRA5 adlican
1779 NKX2-8 NK2 transcription factor related, locus 8
1996 DLNB14 hypothetical protein LOC338657
4691 DKFZP434A0131 Hypothetical protein DKFZP434A0131.
6979 ALS2 alsin
7291 ARHGEF10 Rho guanine nucleotide exchange factor
(GEF) 10
7310 KBTBD11 hypothetical protein LOC9920
8359 BC069659 PRO0641.
9021 PNKP polynucleotide kinase 3′-phosphatase
9113 KAAG1 hypothetical protein LOC353219
9650 THAP5 THAP domain containing 5
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Results show that enforced HA-Lyl1 can associate with the
promoters for several CREB1 target genes. To identify genome-
wide candidate targets for Lyl1 and CREB1 co-regulation we
used ChIP followed by DNA hybridization to a cDNA micro-
array (ChIP-chip). ChIP-chip has been used extensively to map
the location of TF binding sites (TFBS) in the genomes of man,
mouse and yeast. In order to focus on promoter targets with
highly probable regulatory potential, we used a 12K microarray
representation of CpG islands (CGI) in the human genome, that
was previously described [38]. We found an overlap of ∼50%
between Lyl1 and CREB1 genomic targets in HA-Lyl1-K562
cells (Fig. 6A ). This result is surprisingly high but similar to our
analysis of the AML data in which one out of every five genes
was co-regulated by Lyl1 and CREB1. The genes identified by
ChIP-chip are shown in Table 3. The principal gene ontology
categories that showed enrichment by this analysis are shown in
Fig. 6B. Genes associated with loci specific for Lyl1 are
associated with cellular development and cell communication
processes, while the set of genes common to Lyl1 and CREB1
regulates cell cycle, as well as ion and nucleic acid binding
processes. This latter set of genes was enriched in CREB1 targets
that had been previously identified by ChIP-chip analysis of
three different cell lines [39]. Notably, 73% of the gene targets
common for both CREB1 and Lyl1 had been previously
identified as CREB1 target genes (Fig. 6C).
4. Discussion
High levels or mistimed expression of bHLH TFs can initiate
malignant transformation [40–46].We previously found that Lyl1
is over-expressed in themajority of AML clinical samples relative
to its expression in normal bone marrows [19]. This event was
shown to occur as a consequence of chromosomal translocations
or bi-allelic gene expression [9,12,47]. However, epigenetic fac-
tors, such as changes in Lyl1 promoter methylation may also be
implicated, given the wide-spread hypomethylation of the AML
genome. The role of Lyl1 in leukemia is unknown. By analogy
with Tal1 it was suggested that Lyl1 may also compete with E2A/
HEB protein complexes [21] and reduce the formation of homo-
dimers of these TFs, as well as generate hetero-dimers with
abnormal binding activity [48,49]. The change from E2A homo-
dimers to E2A-Tal1 hetero-dimers blocks differentiation [50], but
similar experiments have not been conducted for Lyl1. Over-
expression of Lyl1 reportedly decreased both erythrocytic and
megakaryocytic differentiation but the underlying mechanism
was not investigated [19]. However, in vitro experiments demon-
strated that Lyl1-E2A complexes recognize E boxeswith different
flanking regions, compared to Tal1-E2A complexes and thereby
suggested that the distribution of binding sites in vivo may be
different for these two TFs. The bHLH domains of Tal1 and Lyl1
mediate molecular interactions with a constant set of factors
but the observation that Lyl1 cannot rescue a Tal1 knockout
phenotype [51]suggests that domains other than the bHLH are
required for full functional activity. Furthermore, the fact that Tal1
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sociation with E box-containing promoters demonstrates the
relevance of non-bHLH domains [52]. The results presented here
further illustrate the importance of a non-bHLH domain, namely
the N terminal 140 amino acids of Lyl1. It mediates Lyl1-CREB1
interactions and is not present in Tal1. Expectedly, we did not
observe Tal1-CREB1 interactions. Using expressed CREB1
domains we found that Lyl1 interacts with domains Q2 and
KID. The KID domain is essential for recruiting the transcrip-
tional co-activators p300 and CBP, upon phosphorylation of Ser
133. Experiments with the CREB1 substitution mutant S133A
demonstrated that this phosphorylation event is not required for
the CREB1-Lyl1 interaction. The tripartite interaction Lyl1-
CREB1-p300 occurs in the presence of phosphorylation deficient
CREB1 A133S mutant. This may explain how over-expressed
Lyl1 can interfere with CREB1-dependent gene regulation.
Mitogenic signals trigger cellular proliferation and through the
STAT and MAPK pathways lead to phopshorylation of Ser 133
and other critical CREB1 residues. This series of events ensures
that CREB1 phosphorylation, histone acetlylation by the HAT
activity of recruited p300/CBP and appropriate transcriptional
events are all in step with the mitogenic stimulation. Aberrant
expression of Lyl1 and the subsequent formation of Lyl1 com-
plexes with un-phosphorylated CREB1 can lead to mistimed re-
cruitment of p300/CBP and possibly to out-of step transcriptional
activation events. In addition, formation of Lyl1-E2A complexes
could further compromise physiologic gene regulation by one of
the mechanisms previously discussed.
Id proteins lack the basic DNA binding domains but can
associate with bHLH proteins into complexes devoid of DNA
binding activity [53]. CREB1 was recently identified as a sus-
pected oncoprotein in AML [27,28]. As Id's have been shown
to play a role in malignant transformation through blocking
differentiation [41], while at the same time Id promoters con-
tain conserved CREB1 binding sites, we pursued the possibi-
lity that Lyl1 and CREB1 could regulate Id expression in AML.
By real-time RT-PCR analysis of 19 AML samples we found a
statistically significant correlation between the level of Lyl1 and
Id1 and Id3 expression. Since in addition to Lyl1 expression
many other factors may account for the observed in vivo corre-
lation, we enforced the expression of a tagged Lyl1 construct
in K562 cells and investigated the expression of Id genes in
these cells relative to cells expressing the empty vector. We
found increased levels of Id1, Id3 and Id4 in these experi-
ments. The increase in Id4 expression was not observed in the
clinical samples and may reflect the particular characteristics of
the pro-erythrocytic leukemia line K562, as opposed to the pro-
myelocytic primary cells as well as the heterogenous nature of
primary samples in which variable sets of upstream regulators
can activate the Id genes. In keeping with a direct activation
effect of Lyl1 on Id genes, ChIP experiments showed that HA-
Lyl1 was bound to the promoter regions of Id1, 3 and 4 but not
Id2.
We found that HA-Lyl1 occupies an extended region of the
Id1 promoter. This is in agreement with the presence of several
predicted E box and CREB1 binding sites in this promoter
region (Fig. 4) but raises questions about the specificity of theobserved effect. A review of recent ChIP-chip studies revealed
that for a given TF the number of binding sites outnumber that
of functional sites that can be directly linked to the regulation of
down-stream genes. Euskirchen et al identified thousands of
CREB binding sites along chromosome 22 and estimated that
genome-wide the number of CREB1 binding sites is in the tens
of thousands[54]. A recent study extends that number to over
750,000 half and full-length CREB1 binding sites in the human
genome, but with fewer that 2% being involved in gene
regulation [39]. The issue of the functionality of docking sites
was also raised by experiments with T bet, a T-box family TF
that occupies genomic sites which are un-related to the location
of the genes it regulates [55]. These studies and others suggest
that out of many sites occupied by a given TF only a few are
functional in any given promoter and/or cellular context. By
extension, it is possible that Lyl1 directs Id1 expression from a
limited number of sites but that the presence of other co-factors
may activate Lyl1 bound at different sites. Since Lyl1 forms
multimeric complexes with E2A, LMO2, Ldb1, and GATA
[31,56–58], Lyl1-CREB1 complexes bound to Id1 may become
activated by recruting these proteins and/or factors that interact
directly with CREB1.
The presence of multiple E box sites in the Id1 promoter
complicates the interpretation of the results. We cannot exclude
the possibility that Lyl1-E2A interactions contribute to Id1 up-
regulation. However, using competition experiments with the
minimal murine Id1 promoter identified by Tournay and Be-
nezra [59] we found that complexes containing Lyl1 assemble
only on the Cre sequence and not on the E box or other se-
quences of this promoter. Furthermore, the wt and mutated E
box promoters are equally activated in K562 cells that over-
express untagged Lyl1 compared to the empty vector, but mu-
tation of the Cre site abolishes this effect (see Supplementary
Information). This demonstrates that Lyl1-CREB1 interactions
activate the Id1 promoter, in this system. Furthermore, we ex-
plored the presence of an E box-dependent transcriptional
activating component by performing similar experiments with
Tal1 but did not observe an effect (not shown).
Until recently, only a handful of Tal1 promoters had been
recognized, such as c-kit, retinal aldehyde dehydrogenase and
AK14772, a gene of unknown function [29,60,61]. These genes
all contain closely spaced E2A and GATA sites, or a critical Sp1
site (c-kit). Many new Tal1 promoters were recently identified
[62], but there are still no known genes regulated by Lyl1. To
begin the search for Lyl1 targets we performed ChIP-chip ex-
periments. Because our supply of the polyclonal Lyl1 antibody
[21] was insufficient to carry out these experiments while Lyl1
protein is poorly expressed in K562 cells, we over-expressed
HA-Lyl1 and conducted ChIP-chip experiments using αHA and
αCREB1. Surprisingly, one half of the sites occupied by Lyl1
were also occupied by CREB1. Of these common genes, 73%
had been previously identified as CREB1 targets. These data,
although limited to a 12K representation of the human genome
associated with CpG regions, are suggestive of a widespread co-
regulation of transcription by Lyl1 and CREB1. Nevertheless,
enforced expression of HA-Lyl1 may have generated artifacts,
such as displacement of endogenous complexes or the
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difficult to estimate. However, it is unlikely that artifacts can
account for the approximately 50% overlap between the
genomic Lyl1 and CREB1 sites identified in separate experi-
ments. This is reinforced by the observation that ChIP-chip
experiments performed with cells expressing Flag-Tal1 did not
reveal a significant overlap between Tal1 and CREB1 sites (not
shown). Furthermore, analysis of a landmark study showed that
approximately 20% of the genes expressed in AML clinical
samples correlate with the expression of both Lyl1 and CREB1,
which may co-regulated their expression (Table 2). The 12K
CpG microarray did not include the promoter regions for Id1,
Id3 and Id4 that were amplified in the original ChIP assays
(Fig. 1B) so we could not confirm Lyl1 and CREB1 binding to
their promoters by ChIP-chip.
Recent reports have linked high levels of CREB1 expression
with poor prognosis following chemotherapy in AML patients
[27,28]. This is likely due to the regulation of specific targets by
CREB1. It is recognized that many of the functions mediated by
CREB1 require its activation through a specific phosphorylation
event involving Ser 133 residue, but induction of Ser 133 ac-
counts for the activation of only 2% of all CREB1 targets [54].
This suggests that additional factors are required for the expres-
sion of other CREB1 regulated genes.AsLyl1 andCREB1 are co-
expressed in AML, and as the two proteins can interact in the
absence of Ser133 phosphorylation CREB1-Lyl1 complexes may
contribute to gene deregulation in AML. In keeping with this, we
have shown that Lyl1 could increase the expression of CREB1
responsive genes such as cyclin D3, Egr1 and Id1, which are
highly expressed in AML [25]. It is of note that Lyl1 did not alter
the expression of Bcl2, Bcl-xL or Id2 genes that are also regulated
by CREB1. This inconsistency may be due to the fact that the
Bcl2 and Bcl-xL genes are already maximally stimulated in the
absence of Lyl1, or that other factors are playing a role in the
regulation of these genes in leukemic cells.
In conclusion, this is the first study to show that Lyl1 can
potentially transactivate a different set of genes than Tal1, based
upon the ability of Lyl1 to interact with CREB1. This may
explain in part the difference in phenotypes in leukemias in
which Lyl1 or Tal1 are the predominant bHLH oncogenes and
may open a new avenue of research into the function of these
two oncoproteins in AML.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.bbamcr.2007.11.015.
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